Bangalore, Aug 26 (UNI) Genzyme Corp, a global leader in biotechnology and Medicines for Malaria Venture (MMV), a not-for-profit virtual Research and Development organisation today announced a new collaboration with Advinus Therapeutics Ltd.
The collaboration was aimed at developing new, improved treatments for specific patient groups most at risk for malaria, an often-fatal infectious disease of developing countries, particularly affecting pregnant women and infants.
''Malaria kills between one and two million people annually, with the majority of victims being children under five and pregnant women,'' said Dr Chris Hentschel, President and Chief Executive Officer of MMV.
''New antimalarial agents are urgently needed to stop this unacceptable loss of life, with eradication as our long-term objective. The pipeline of new molecules that are effective against malaria must be made more robust so that we can develop the next generation of powerful treatments,'' he added.
City-based Advinus, promoted by TATA, a life sciences research and development company has extensive expertise in pharmaceutical R&D.
Dr Rashmi Barbhaiya, CEO of Advinus said '' India is one of the few countries in the world that has not only the disease burden, but also the capability to research and develop new therapies for these diseases.'' UNI MSP MV ROY AK VC2000